Although the FDA approval of lenacapavir as a twice-yearly form of preexposure prophylaxis (PrEP) is “momentous,” cost and access curb excitement, according to Jeremiah Johnson, executive director of ...

WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.

Tamar Braxton has announced a new brand partnership with Gilead Sciences. The music veteran will help educate and raise ...

In rural India, mycetoma—a painful, neglected disease from minor wounds—cripples workers, causing disability, poverty, and stigma. Delayed diagnosis and costly treatment worsen the crisis.